Oncology Today with Dr Neil Love

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:
Introduction (00:00)
Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
Adjuvant CDK4/6 Inhibitor Therapy (17:14)
Practical Considerations with CDK4/6 Inhibitors (29:57)
Monitoring and Management of Cytopenias (42:02)
CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
Management of Gastrointestinal Adverse Events (1:03:47)
CDK4/6 Inhibitors in Unique Populations (1:10:41)
Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics:
Introduction (0:00)
Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45)
Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08)
Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman, including the following topics:
The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
Zanubrutinib-based therapy for treatment-naïve CLL (12:32)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)
Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)
Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)

CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:
Introduction (0:00)
Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)
Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)
Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)
Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)
Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)

CME information and select publications